Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – September 13, 2023 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Adams

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://www.zoomgov.com/webinar/register/WN_0aEa3CWFRR6lyxMLGdkOvg
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 160 522 8313
Passcode: 246928

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. July 12, 2023 DUR Board Meeting Minutes
   B. July 12, 2023 DUR Board Recommendations Memorandum
   C. August 9, 2023 DUR Board Recommendations Memorandum

Items to be presented by Dr. Muchmore, Chairman:

4. **Action Item – Approval of DUR Board Interim Vice Chair**
   A. Nomination and Vote on DUR Board Interim Vice Chair

Items to be presented by Dr. Reynolds, Dr. Wilson, Dr. Muchmore, Chairman:

5. **Update on Medication Coverage Authorization Unit/ Nonalcoholic Fatty Liver Disease (NAFLD) Update – See Appendix B**
   A. Pharmacy Help Desk Activity for August 2023
   B. Medication Coverage Activity for August 2023
   C. NAFLD Update

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Leqembi® (Lecanemab-irmb) and Update the Approval Criteria for the Alzheimer's Disease Medications – See Appendix C**
   A. Market News and Updates

B. Leqembi® (Lecanemab-irmb) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Vyjuvek™ (Beremagene Geperpavec-svdt) – See Appendix D**

A. Market News and Updates
B. Vyjuvek™ (Beremagene Geperpavec-svdt) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

8. **Action Item – Vote to Prior Authorize Kyzatrex™ (Testosterone Undecanoate Capsule) and Update the Approval Criteria for the Testosterone Products – See Appendix E**

A. Market News and Updates
B. Kyzatrex™ (Testosterone Undecanoate Capsule) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

9. **Action Item – Vote to Prior Authorize Brixadi™ (Buprenorphine Extended-Release Injection), Nalocet® (Oxycodone/Acetaminophen Tablet), and Prolate™ (Oxycodone/Acetaminophen Oral Solution and Tablet) and to Update the Approval Criteria for the Opioid Analgesics and Medication Assisted Treatment (MAT) Medications – See Appendix F**

A. Market News and Updates
B. Product Summaries
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

10. **Action Item – Vote to Update the Approval Criteria for the Topical Corticosteroids – See Appendix G**

A. Market News and Updates
B. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

11. **Action Item – Vote to Update the Approval Criteria for the Intravenous (IV) Iron Products – See Appendix H**

A. Market News and Updates
B. College of Pharmacy Recommendations

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

12. **Action Item – Vote to Prior Authorize Xacduro® (Sulbactam/Durlobactam) and Update the Approval Criteria for the Various Systemic Antibiotics – See Appendix I**

A. Market News and Updates

B. Xacduro® (Sulbactam/Durlobactam) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

13. Action Item – Vote to Prior Authorize Cuvrior™ (Trientine Tetrahydrochloride) – See Appendix J

A. Cuvrior™ (Trientine Tetrahydrochloride) Product Summary
B. College of Pharmacy Recommendations

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

14. Action Item – Annual Review of Tepezza® (Teprotumumab-trbw) – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of Tepezza® (Teprotumumab-trbw)
C. Prior Authorization of Tepezza® (Teprotumumab-trbw)
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Tepezza® (Teprotumumab-trbw)

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

15. Action Item – Annual Review of Oxlumo® (Lumasiran) – See Appendix L

A. Current Prior Authorization Criteria
B. Utilization of Oxlumo® (Lumasiran)
C. Prior Authorization of Oxlumo® (Lumasiran)
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Oxlumo® (Lumasiran)

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

16. Action Item – Annual Review of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators – See Appendix M

A. Current Prior Authorization Criteria
B. Utilization of CFTR Modulators
C. Prior Authorization of CFTR Modulators
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of CFTR Modulators

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

17. Action Item – Annual Review of Gattex® [Teduglutide (rDNA origin)] – See Appendix N

A. Current Prior Authorization Criteria
B. Utilization of Gattex® [Teduglutide (rDNA origin)]
C. Prior Authorization of Gattex® [Teduglutide (rDNA origin)]
D. Market News and Updates

E. College of Pharmacy Recommendations
F. Utilization Details of Gattex® [Teduglutide (rDNA origin)]

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

18. Action Item – Annual Review of Synagis® (Palivizumab) – See Appendix O

A. Current Prior Authorization Criteria
B. Utilization of Synagis® (Palivizumab)
C. Prior Authorization of Synagis® (Palivizumab)
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of Synagis® (Palivizumab)

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

19. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Orserdu™ (Elacestrant) – See Appendix P

A. Current Prior Authorization Criteria
B. Utilization of Breast Cancer Medications
C. Prior Authorization of Breast Cancer Medications
D. Market News and Updates
E. Orserdu™ (Elacestrant) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

20. Annual Review of Zinplava™ (Bezlotoxumab) and 30-Day Notice to Prior Authorize Rebyota® (Fecal Microbiota, Live-jslm) and Vowst™ (Fecal Microbiota Spores, Live-brpk) – See Appendix Q

A. Current Prior Authorization Criteria
B. Utilization of Zinplava™ (Bezlotoxumab)
C. Prior Authorization of Zinplava™ (Bezlotoxumab)
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Zinplava™ (Bezlotoxumab)

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

21. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

22. Future Business* (Upcoming Product and Class Reviews)

A. Anemia Medications
B. Hepatitis C Medications
C. Muscular Dystrophy Medications
D. Targeted Immunomodulator Agents

*Future product and class reviews subject to change.

23. Adjournment

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.